Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Fierce Biotech

Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Benzinga.com

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE:MRK) on Wednesday announced ...
Seeking Alpha

Gilead raises 2025 HIV revenue growth outlook to 5% as Biktarvy and Descovy drive momentum

Daniel O'Day, Chairman & CEO, stated that "our third quarter earnings underscore the growing momentum you're seeing from Gilead today, which is driven by our strong portfolio and the impressive ...
Drug Store News

Gilead settles Biktarvy patent disputes

Gilead has settled patent disputes with three generic companies for Biktarvy, per a Yahoo Finance report. Gilead settlement agreements are with Lupin, Cipla and Laurus Labs, who had filed abbreviated ...